Replies to post #684583 on NorthWest Biotherapeutics Inc (NWBO)

[Nemesis18]

This is so F'in awful to watch. I am sick and tired of the silence and nonsense. I have 320,000 shares I am happy to sell to all the apologists at my break even at .74.

Bloody hell,! that’s a lot of your hard earnt cash riding on this gamble !

I get nervous / excited / fed up spending £10 on the Lottery .!

I do sincerely wish you all the best in the near & long term, as that’s a crazy amount to have on risk.
It’s all your call now Sir. If you can get to near break even, then live to fight another day, maybe ?

Don’t give a crap about what others might think, if you cash out quickly, for this is your real money, and at that level, it ain’t a game Sir

[FeMike]

This is so F'in awful to watch. I am sick and tired of the silence and nonsense. I have 320,000 shares I am happy to sell to all the apologists at my break even at .74. Please let me know since several of you are happy to wait forever and excuse the fiduciary malfeasance of mgmt..

I know it's not fun and I'm right there with ya' on the terrible management, but just give it to at least the timeline we have.

I have told y'all (and management has matched this sentiment) that there just isn't going to be news until MHRA decision. We're waiting on that for all the other wheels to start rolling. It may well be a huge train, but none of the cars will start moving until the engine (MHRA approval) goes.

We had confirmation when management's paid spokespeople (Smith on Stocks and Hoffmann) both put out at almost exactly the same time (January) that the company is going to be tied up for months with MHRA and won't be working on anything else. We likely still have a couple more months of quiet but interest should start picking up in June, and in my opinion the big near term run will be -before- approval, not after.

It's frustrating to sit in the dark and wait, and it's too risky for long term holders to have sold in January and bought back in (we're all just guessing here, we could get approval tomorrow, hence the risk); but I think we got pretty solid guidance at the end of December on when to expect developments and we're just not quite there yet.